David Hung makes a quick, abrupt ex­it at Ax­o­vant af­ter hu­mil­i­at­ing set­backs

A month af­ter ex­pe­ri­enc­ing one of the most hu­mil­i­at­ing set­backs in biotech, David Hung is bow­ing out as CEO of Ax­o­vant $AX­ON.

Hung, you’ll re­call, had on­ly re­cent­ly com­plet­ed a $14 bil­lion deal to sell Medi­va­tion to Pfiz­er when he agreed to take the helm at Vivek Ra­maswamy’s Alzheimer’s com­pa­ny just 10 months ago. His new deal gave him a di­rect line to a po­ten­tial for­tune, pro­vid­ed the drug — once tout­ed as “a great drug can­di­date” by Roivant founder Vivek Ra­maswamy — ac­tu­al­ly worked.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER